I went back and watched the video again. Gregg Linn

New Post Public Reply Private Reply Replies (2) Message Board
investorxc
I went back and watched the video again. Gregg Linn stresses how it doesn't make sense for a small company to spend the money to develop a drug like OvaDx and again they are going to license or sell it. He also talks at the beginning how when he was speaking with GC and GC said he planned to spin the Dx division out and Greg said " do you think this is really good time to do this?- I've got a better idea"

I think the reason GC sold the Dx to ADVX is becasue ADVX is going to be licensing OvaDX in the near future and will be getting A LOT of upfront cash. Once they do that, they won't have any assets left so they needed something to replace OvaDx and they will then have the cash to develop the AMBS assets- more cash than what GC could have raised on his own. I could see OvaDX getting a big upfront payment- maybe several tens of millions and then royalties/ milestones on the back-end. He is apparently in talks with Roche which he has already said, but probably others as well. These deals take many months to do- there is a lot of due diligence and negotiating. There seems to be a lot of consolidation in the DX business. Pretty much everything is owned by a few big companies like Quest and Lab Corp, so I would guess they would all interested.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Oxford Lane Capital Corp. Highlights Q2 Financial Achievements

Updated Category News Views 88

Oxford Lane Capital Corp. Reports Strong Quarterly Outcomes In an exciting update from Oxford Lane Capital Corp. (NASDAQ: OXLC), the company has announced its recent net asset value (NAV) and outstanding financial results. During the latest announcement, made in early November, Oxford Lane showcased a strong financial performance for the quarter ended September 30, 2024,...

Continue Reading
Japan's Facial Injectables Market: Growth, Trends, and Innovations

Updated Category News Views 176

Understanding the Growth of Japan's Facial Injectables Market The Japan facial injectables market is on a promising growth trajectory, having been valued at approximately US$ 508 million recently. Experts project it will soar to over US$ 1.12 billion by the end of the next decade. This remarkable growth is attributed to a compound annual growth rate (CAGR) of 9.52%,...

Continue Reading
Unleashing the Power of K-Culture with Pepe Buldak's Surge

Updated Category News Views 338

Emergence of Pepe Buldak: A New Era in Meme Coins Introducing Pepe Buldak, the innovative meme coin inspired by the beloved Korean spicy chicken dish, Buldak. This project blends the cultural significance of Korean cuisine with the playful and viral nature of meme culture, creating a unique narrative that captures the attention of investors and culture enthusiasts alike....

Continue Reading
Optimizing Your Investment: Insights on Zeta Global Holdings Options

Updated Category News Views 235

Understanding the Buzz in Options Trading for Zeta Global Holdings Investors with significant capital have adopted a bullish perspective on Zeta Global Holdings ZETA. This heightened interest warrants attention, especially from retail traders who want to stay informed. Today, unexpected trades surfaced in publicly available options data we monitor, indicating that either...

Continue Reading
FXAIR Revolutionizes Private Jet Charter with Stellar Growth

Updated Category News Views 198

FXAIR: A New Era in Private Jet Charter Services FXAIR has become a standout in the private jet charter industry, achieving remarkable growth over the years. Unlike the general trend of decline in the market, this innovative company has seen a growth rate of 190% since its launch. This impressive success is a testament to FXAIR's commitment to providing sophisticated and...

Continue Reading